Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

¹H NMR Chemical Shift Equivalence: Homotopic and Heterotopic Protons01:03

¹H NMR Chemical Shift Equivalence: Homotopic and Heterotopic Protons

Protons in identical electronic environments within a molecule are chemically equivalent and have the same chemical shift. The replacement test is a useful tool to identify chemical equivalence and predict NMR spectra. A substituent replaces each of the protons being examined and the resulting molecules are compared. If the same molecule is obtained, the protons are equivalent or homotopic. Replacement of any hydrogens in ethane by chlorine yields chloroethane because all six protons are...
Pharmaceutical Equivalents01:26

Pharmaceutical Equivalents

As defined by regulatory standards, pharmaceutical equivalents require generic drug products to have identical dosage forms and chemically identical active pharmaceutical ingredients (APIs). They must adhere to compendial or applicable standards for potency, content uniformity, disintegration times, and dissolution rates. In the case of modified-release dosage forms, variations in drug content are permissible as long as the delivered amount remains consistent with the innovator drug product.
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence01:27

Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence

Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
Antipsychotic Drugs: Typical and Atypical Agents01:21

Antipsychotic Drugs: Typical and Atypical Agents

Antipsychotic drugs are classified into first-generation (typical) drugs including phenothiazines; and second-generation (atypical) drugs. Chlorpromazine hydrochloride (Thorazine), a phenothiazine derivative, broadly impacts the central, autonomic, and endocrine systems. This drug, along with typical agents like haloperidol (Haldol), primarily works by antagonizing D2 receptors, thus reducing dopaminergic neurotransmission. However, typical antipsychotics can cause side effects such as sedation...
Adrenergic Agonists: Chemistry and Structure-Activity Relationship01:16

Adrenergic Agonists: Chemistry and Structure-Activity Relationship

Adrenergic agonists' structure-activity relationship (SAR) determines their selectivity and efficacy. These agonists comprise a phenylethylamine moiety with an aromatic ring and an ethylamine side chain.
Aromatic ring substitutions: Substituting the aromatic ring with –OH groups at positions 3 and 4 yields catecholamines (e.g., epinephrine), which have a high affinity for adrenoceptors. Hydrogen bonding between –OH groups and receptors enhances adrenergic activity.
Separation of the aromatic...
Composition of Polyprotic Acid Solutions as a Function of pH01:19

Composition of Polyprotic Acid Solutions as a Function of pH

Polyprotic acids of the type H2M constitute two ionizable protons. As a result, on titration with a base, they exhibit two equivalence points in the titration curve. During titration, the species H2M, HM−, and M2− will be present in the solution at different points. The fractions of H2M, HM−, and M2− present at the various instances of the titration are denoted by α0, α1, and α2, respectively.
A graph with the alpha values is plotted against the volume of base added during titration. Here, a...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The Fracture Phenotypes in Women and Men of 50 Years and Older with a Recent Clinical Fracture.

Current osteoporosis reports·2024
Same author

The Dutch multidisciplinary guideline osteoporosis and fracture prevention, taking a local guideline to the international arena.

Archives of osteoporosis·2024
Same author

Course and predictors of upper leg muscle strength over 48 months in subjects with knee osteoarthritis: Data from the osteoarthritis initiative.

Osteoarthritis and cartilage open·2022
Same author

Evaluation of treatment outcome using the Patient Specific Functional Scale in knee osteoarthritis patients undergoing multidisciplinary rehabilitation.

Osteoarthritis and cartilage open·2022
Same author

Determinants of pain and activity limitations in foot osteoarthritis: An exploratory cross-sectional study in the Amsterdam-foot cohort.

Osteoarthritis and cartilage open·2022
Same author

In RA patients without prevalent CVD, incident CVD is mainly associated with traditional risk factors: A 20-year follow-up in the CARRÉ cohort study.

Seminars in arthritis and rheumatism·2022

Related Experiment Video

Updated: Jun 26, 2026

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS
10:13

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

PTH-analogs: comparable or different?

H J J Verhaar1, W F Lems2

  • 1Department of Geriatric Medicine, University Medical Centre Utrecht, P.O. Box 85.500 (Room B05.256), 3508 GA Utrecht, The Netherlands.

Archives of Gerontology and Geriatrics
|January 7, 2009
PubMed
Summary
This summary is machine-generated.

Parathyroid hormone (PTH) 1-34 and PTH 1-84 both effectively reduce vertebral fractures in osteoporosis. PTH 1-34 also reduced non-vertebral fractures, while PTH 1-84 showed more side effects like nausea.

More Related Videos

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays
11:28

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses
06:52

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses

Published on: January 18, 2013

Related Experiment Videos

Last Updated: Jun 26, 2026

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS
10:13

Fentanyl Analog Screening using LC-TIMS-TOF MS/MS

Published on: November 8, 2024

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays
11:28

Recording Network Activity in Spinal Nociceptive Circuits Using Microelectrode Arrays

Published on: February 9, 2022

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses
06:52

Manufacturing and Using Piggy-back Multibarrel Electrodes for In vivo Pharmacological Manipulations of Neural Responses

Published on: January 18, 2013

Area of Science:

  • Endocrinology
  • Pharmacology
  • Orthopedics

Background:

  • Osteoporosis treatment requires effective anabolic agents.
  • Parathyroid hormone (PTH) analogs, PTH 1-34 and PTH 1-84, are used for severe osteoporosis.
  • Direct comparative studies on their efficacy and safety are lacking.

Purpose of the Study:

  • To compare the effectiveness and safety of PTH 1-34 and PTH 1-84.
  • To highlight similarities and differences in their therapeutic profiles.
  • To inform clinical decision-making for osteoporosis management.

Main Methods:

  • Review of existing literature on PTH 1-34 and PTH 1-84 clinical trials.
  • Analysis of fracture reduction data (vertebral and non-vertebral).
  • Evaluation of reported side effect profiles and anabolic mechanisms.

Main Results:

  • Both PTH 1-34 and PTH 1-84 demonstrated significant reduction in vertebral fractures.
  • PTH 1-34 showed efficacy in reducing non-vertebral fractures, unlike PTH 1-84.
  • PTH 1-84 exhibited a higher incidence of hypercalcemia, hypercalciuria, and nausea compared to teriparatide (PTH 1-34).
  • Both agents possess strong anabolic actions distinct from bisphosphonates and strontium ranelate.

Conclusions:

  • PTH 1-34 and PTH 1-84 are valuable additions to osteoporosis therapy.
  • PTH 1-34 has more available long-term data and demonstrated broader fracture protection.
  • Differences in side effect profiles require further investigation through comparative studies.